Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 635Glioblastoma 566Glioma 405Neuroblastoma 174Neoplasms 123Astrocytoma 106Central Nervous System Neoplasms 103Medulloblastoma 87Breast Neoplasms 86Meningioma 82Carcinoma, Non-Small-Cell Lung 78Melanoma 77Lung Neoplasms 69Sarcoma 66Ependymoma 64Neurofibromatosis 1 63Recurrence 50Oligodendroglioma 48Neoplasm Metastasis 48Osteosarcoma 47Meningeal Carcinomatosis 46Rhabdomyosarcoma 45Diffuse Intrinsic Pontine Glioma 44Pheochromocytoma 43Rhabdoid Tumor 41Paraganglioma 41Gliosarcoma 40Sarcoma, Ewing 39Pancreatic Neoplasms 39Colorectal Neoplasms 33

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tauopathies × CNS × 1 year × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡